# Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica

> **NCT07279688** · PHASE3 · NOT_YET_RECRUITING · sponsor: **University Hospital, Brest** · enrollment: 140 (estimated)

## Conditions studied

- Polymyalgia Rheumatica (PMR)

## Interventions

- **DRUG:** Baricitinib 4 MG Oral Tablet
- **DRUG:** Baricitinib 2 MG Oral Tablet
- **DRUG:** Placebo 4 mg
- **DRUG:** Placebo 2 mg

## Key facts

- **NCT ID:** NCT07279688
- **Lead sponsor:** University Hospital, Brest
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-12
- **Primary completion:** 2028-11-12
- **Final completion:** 2029-06-12
- **Target enrollment:** 140 (ESTIMATED)
- **Last updated:** 2025-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07279688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07279688, "Justification And Evaluation of Baricitinib Plus Corticosteroids Versus corticosteroiDs Alone in pOlymyalgia RhEumatica". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07279688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*